biodexa-logo-square (1).png
Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT Grant
16 sept. 2024 08h30 HE | Biodexa Pharmaceuticals PLC
September 16, 2024 Biodexa Pharmaceuticals PLC Announces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantFunds to Advance Development of Phase 3 Asset ...
biodexa-logo-square (1).png
Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement
23 juil. 2024 08h30 HE | Biodexa Pharmaceuticals PLC
July 23, 2024 Biodexa Pharmaceuticals PLC Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”)...
7HP935 combined with umbilical cord blood may represent a new and better option for patients in need of HSCT.
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the Clinic
03 juin 2024 12h57 HE | 7 Hills Pharma
Houston biotech awarded $4.7MM in homegrown Texas support for new technology to safely improve the treatment of advanced blood cancers and genetic diseases
biodexa-logo-square (1).png
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)
26 avr. 2024 08h30 HE | Biodexa Pharmaceuticals PLC
April 26, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)...
7 Hills Logo.png
7 Hills Pharma Surpasses $25MM Milestone in Nondilutive Funding
22 mai 2023 13h05 HE | 7 Hills Pharma
HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- 7 Hills Pharma LLC (“7 Hills” or “7HP”) announced today that it has been awarded $13.5MM in nondilutive grant funds from the Cancer Prevention &...
Logo.jpg
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS 
11 avr. 2022 10h00 HE | Invectys, Inc.
Houston, Texas, USA, April 11, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company which is developing a next generation of therapies to meet the needs...
Logo.jpg
INVECTYS INC. TO PARTICIPATE IN THE 2021 ROTH VIRTUAL HEALTHCARE PRIVATE COMPANY FORUM ON JUNE 28TH, 2021
25 juin 2021 11h30 HE | Invectys, Inc.
Houston, Texas, USA, June 25, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. a clinical-stage immunotherapy company headquartered in Houston and dedicated to the development of a new generation of products...
Logo.jpg
Invectys nominates Rosemary Williams, CPA, as Vice-President for Administration and Controller
01 juin 2021 11h00 HE | Invectys, Inc.
Houston, TX, USA, June 01, 2021 (GLOBE NEWSWIRE) -- Invectys Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the...